<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177928</url>
  </required_header>
  <id_info>
    <org_study_id>CCMPNS</org_study_id>
    <nct_id>NCT03177928</nct_id>
  </id_info>
  <brief_title>Cardiac Changes in Myeloproliferative Neoplasms</brief_title>
  <official_title>Functional and Morphological Cardiac Changes in Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myeloproliferative neoplasms are heterogeneous group of clonal hematopoietic stem cell
      neoplasms with excessive proliferation of one or more of the erythroid, megakaryocytic, or
      myeloid lineages and relatively normal maturation resulting in increased numbers of red
      cells, platelets, and/or granulocytes in the peripheral blood. Constitutive tyrosine kinase
      activation appears to be a common pathogenetic mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to worldwide study of prevalence of myeloproliferative neoplasms revealed:

      Incidence of polycythemia vera ranged 0.01 to 2.61 per 100.000 population and the prevalence
      ranging from 0.49 to 46.88 per 100.000 population. Incidence of essential thrombocythemia is
      0.21 to 2.27 per 100.000 population, prevalence ranging between 11.00 - 42.51 per 100.000
      population.

      Primary myelofibrosis incidence is 1.15 -4.99 per 100.000 population and prevalence ranging
      between 1.76 - 4.05 per 100.000 population.In previous studies, cardiac involvement including
      coronary arterial thrombosis, myocardial infarction, pulmonary hypertension, asymptomatic
      pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular
      stenosis and valvular stenosis that occur in myeloproliferative neoplasms. There is a few
      number of studies in which cardiac lesions were evaluated in myeloproliferative neoplasms by
      using transthoracic echocardiography but still inadequate, so we need to understand more
      about cardiovascular complications in myeloproliferative neoplasms.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with cardiac complications in myeloproliferative diseases.</measure>
    <time_frame>30 minutes</time_frame>
    <description>cardiac complications as valvular changes, ejection fraction changes, pulmonary hypertension</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transthorathic echocardiogram</intervention_name>
    <description>In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>control group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic criteria of myeloproliferative neoplasms.

        Exclusion Criteria:

          -  Extreme body weight e.g., morbid obesity.

          -  Cardiac disease.

          -  Cerebrovascular disorders.

          -  Diabetes mellitus.

          -  Dyslipidemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Osama A Ibrahim, Proffessor.</last_name>
    <phone>00201006372498</phone>
    <email>oibrahiem@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed B Ahmed, lecturer.</last_name>
    <phone>00201009820300</phone>
    <email>ahmadbahei@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2015 Sep;90(9):850. doi: 10.1002/ajh.23984. Epub 2015 Mar 30.</citation>
    <PMID>26299877</PMID>
  </reference>
  <reference>
    <citation>Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user's manual. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542. Review.</citation>
    <PMID>27913526</PMID>
  </reference>
  <reference>
    <citation>Campbell A. Now I know why. Front Nurs Serv Q Bull. 1968 Winter;43(3):7-9.</citation>
    <PMID>5183970</PMID>
  </reference>
  <reference>
    <citation>Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014 Jun;89(6):581-7. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):850.</citation>
    <PMID>24971434</PMID>
  </reference>
  <reference>
    <citation>Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.</citation>
    <PMID>23768070</PMID>
  </reference>
  <reference>
    <citation>Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016 Nov;30(6):453-459. doi: 10.1016/j.blre.2016.06.001. Epub 2016 Jun 11. Review.</citation>
    <PMID>27341755</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>AKAli</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

